Literature DB >> 15765234

In vivo uptake of [11C]choline does not correlate with cell proliferation in human prostate cancer.

Anthonius J Breeuwsma1, Jan Pruim, Maud M Jongen, Albert J Suurmeijer, Wim Vaalburg, Rien J Nijman, Igle J de Jong.   

Abstract

PURPOSE: Prostate cancer is the second leading cause of death from cancer among US men. Positron emission tomography (PET) with [(11)C]choline has been shown to be useful in the staging and detection of prostate cancer. The background of the increased uptake of choline in human prostate cancer is not completely understood. The aim of this study was to prospectively investigate the relationship between the [(11)C]choline uptake and the cell proliferation in human prostate cancer.
METHODS: Prostate cancer tissue from 18 patients who had undergone a radical prostatectomy for histologically proven disease was studied. An [(11)C]choline PET scan was performed prior to surgery. Post-prostatectomy specimens were prepared and stained with the antibody MIB-1 for Ki-67, which depicts proliferation. Two independent observers counted the amount of stained nuclei per specimen.
RESULTS: Prostate cancer showed Ki-67 staining and high uptake of [(11)C]choline. Statistical analysis showed no significant correlation between [(11)C]choline uptake and Ki-67 staining (R=0.23; P=0.34). No significant relationships were found between the uptake of [(11)C]choline (SUV) and either preoperative PSA (R=0.14; P=0.55) or Gleason sum score (R=0.28; P=0.25).
CONCLUSION: In vivo uptake of [(11)C]choline does not correlate with cell proliferation in human prostate cancer as depicted by Ki-67. Our results suggest that a process other than proliferation is responsible for the uptake of [(11)C]choline in prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15765234     DOI: 10.1007/s00259-004-1741-4

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  28 in total

1.  Blood metabolism of [methyl-11C]choline; implications for in vivo imaging with positron emission tomography.

Authors:  A Roivainen; S Forsback; T Grönroos; P Lehikoinen; M Kähkönen; E Sutinen; H Minn
Journal:  Eur J Nucl Med       Date:  2000-01

Review 2.  Handling and pathology reporting of radical prostatectomy specimens.

Authors:  Rodolfo Montironi; Theodorus van der Kwast; Liliane Boccon-Gibod; Aldo V Bono; Laurent Boccon-Gibod
Journal:  Eur Urol       Date:  2003-12       Impact factor: 20.096

Review 3.  Imaging clinically localized prostate cancer.

Authors:  Rajveer S Purohit; Katsuto Shinohara; Maxwell V Meng; Peter R Carroll
Journal:  Urol Clin North Am       Date:  2003-05       Impact factor: 2.241

4.  In vivo proton MR spectroscopy reveals altered metabolite content in malignant prostate tissue.

Authors:  A Heerschap; G J Jager; M van der Graaf; J O Barentsz; J J de la Rosette; G O Oosterhof; E T Ruijter; S H Ruijs
Journal:  Anticancer Res       Date:  1997 May-Jun       Impact factor: 2.480

5.  Cancer statistics, 2002.

Authors:  Ahmedin Jemal; Andrea Thomas; Taylor Murray; Michael Thun
Journal:  CA Cancer J Clin       Date:  2002 Jan-Feb       Impact factor: 508.702

6.  Experience with carbon-11 choline positron emission tomography in prostate carcinoma.

Authors:  J Kotzerke; J Prang; B Neumaier; B Volkmer; A Guhlmann; K Kleinschmidt; R Hautmann; S N Reske
Journal:  Eur J Nucl Med       Date:  2000-09

7.  Development of (18)F-fluoroethylcholine for cancer imaging with PET: synthesis, biochemistry, and prostate cancer imaging.

Authors:  Toshihiko Hara; Noboru Kosaka; Hiroichi Kishi
Journal:  J Nucl Med       Date:  2002-02       Impact factor: 10.057

8.  Ki-67 immunolabeling in pre-malignant lesions and carcinoma of the prostate. Histological correlation and prognostic evaluation.

Authors:  E Muñoz; F Gómez; J I Paz; I Casado; J M Silva; M T Corcuera; M J Alonso
Journal:  Eur J Histochem       Date:  2003       Impact factor: 3.188

9.  Determining prognosis of clinically localized prostate cancer by immunohistochemical detection of mutant p53.

Authors:  H J Stricker; J K Jay; M D Linden; P Tamboli; M B Amin
Journal:  Urology       Date:  1996-03       Impact factor: 2.649

10.  Ki-67 staining index predicts distant metastasis and survival in locally advanced prostate cancer treated with radiotherapy: an analysis of patients in radiation therapy oncology group protocol 86-10.

Authors:  Rile Li; Kateri Heydon; M Elizabeth Hammond; David J Grignon; Mack Roach; Harvey B Wolkov; Howard M Sandler; William U Shipley; Alan Pollack
Journal:  Clin Cancer Res       Date:  2004-06-15       Impact factor: 12.531

View more
  35 in total

1.  Could choline PET play a role in malignancies other than prostate cancer?

Authors:  Cristina Nanni; Domenico Rubello; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-09-26       Impact factor: 9.236

2.  11C/ 18F-choline PET or 11C/18F-acetate PET in prostate cancer: may a choice be recommended?

Authors:  Cristina Nanni; Paolo Castellucci; Mohsen Farsad; Domenico Rubello; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-10       Impact factor: 9.236

3.  Planar and SPECT imaging in the era of PET and PET-CT: can it survive the test of time?

Authors:  Abass Alavi; Sandip Basu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-08       Impact factor: 9.236

4.  Do we have to withdraw antiandrogenic therapy in prostate cancer patients before PET/CT with [11C]choline?

Authors:  Giampiero Giovacchini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-11       Impact factor: 9.236

Review 5.  PET and PET/CT with radiolabeled choline in prostate cancer: a critical reappraisal of 20 years of clinical studies.

Authors:  Giampiero Giovacchini; Elisabetta Giovannini; Rossella Leoncini; Mattia Riondato; Andrea Ciarmiello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-04-14       Impact factor: 9.236

6.  Do androgens control the uptake of 18F-FDG, 11C-choline and 11C-acetate in human prostate cancer cell lines?

Authors:  Kimy M Emonds; Johannes V Swinnen; Wytske M van Weerden; Frank Vanderhoydonc; Johan Nuyts; Luc Mortelmans; Felix M Mottaghy
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-07-06       Impact factor: 9.236

7.  Androgen deprivation therapy influences the uptake of 11C-choline in patients with recurrent prostate cancer: the preliminary results of a sequential PET/CT study.

Authors:  Chiara Fuccio; Riccardo Schiavina; Paolo Castellucci; Domenico Rubello; Giuseppe Martorana; Monica Celli; Claudio Malizia; Marta Barios Profitos; Maria Cristina Marzola; Vincenzina Pettinato; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-07-06       Impact factor: 9.236

Review 8.  Molecular imaging of prostate cancer: PET radiotracers.

Authors:  Hossein Jadvar
Journal:  AJR Am J Roentgenol       Date:  2012-08       Impact factor: 3.959

Review 9.  Functional imaging for prostate cancer: therapeutic implications.

Authors:  Carina Mari Aparici; Youngho Seo
Journal:  Semin Nucl Med       Date:  2012-09       Impact factor: 4.446

10.  [(11)C]choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy.

Authors:  Giampiero Giovacchini; Maria Picchio; Elisa Coradeschi; Vincenzo Scattoni; Valentino Bettinardi; Cesare Cozzarini; Massimo Freschi; Ferruccio Fazio; Cristina Messa
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-01-16       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.